Facts and Statistics about Common Women’s Cancers: Breast, Gynaecological, Cervical and Ovarian Posted on October 23, 2016September 18, 2019 by Carly du Toit Each day up to 170 women in Australia are diagnosed with cancer. With this alarming figure, ACRF is determined to make a difference in the lives of Australian women through cancer research. To raise awareness of the cancers that affect women this month, we’ve compiled a few interesting facts and stats. Women’s cancer facts and statistics at a glance 1 in 3 women will be diagnosed with some form of cancer before the age of 85 There are over 200 types of cancer that can affect women The most common cancers diagnosed with Australian women are: non-melanoma of the skin, breast, colorectal, leukaemia and lymphoma Thanks to research, survival rates were highest for women diagnosed with thyroid cancer (97%), lip cancer (94%) and melanoma of the skin (94%) Breast cancer facts and statistics 1 in 8 women diagnosed with breast cancer before the age of 85 Breast cancer is the most common cancer diagnosed in Australian women Thanks to research, the 5 year survival rate is just over 90% Known risk factors are diet, alcohol consumption and physical inactivity Breast cancer in men accounts for around 1% of all breast cancer occurrences Gynaecological cancer facts and statistics The risk of an individual being diagnosed with a gynaecological cancer by age 85 is 1 in 22. Gynaecological cancers were the 3rd most commonly diagnosed cancer among females in Australia. Known risk factors include age The five year survival rate is 68% Gynaecological cancers include malignant neoplasms of vulva, vagina, cervix, uterus, placenta and ovaries For more information on gynaecological cancer, click here. Cervical cancer facts and statistics The risk of a woman being diagnosed with cervical cancer by the age of 85 is 1 in 162. The five-year survival rate for women with cervical cancer is 72% In 2009, cervical cancer was the third most commonly diagnosed gynaecological cancer in Australia Since the introduction of the National Cervical Screening Program in 1991, the number of new cases of cervical cancer for women of all ages almost halved In 2006, Professor Ian Frazer and his team at the University of Queensland discovered a vaccine to prevent HPV, protecting women against most types of cervical cancer Ovarian cancer facts and statistics 1 in 75 women diagnosed with ovarian cancer before the age of 85 Most common most common cause of gynaecological cancer death in Australia More research is needed to increase the 5 year survival rate from 45% Known risk factors are family history and genetic susceptibility as well as obesity and physical inactivity Symptoms are often vague and can be similar to the symptoms of many other conditions Donate or Fundraise To Support Women’s Cancer Research By donating, fundraising for and supporting cancer research into all cancers that affect women, you are helping to fund the next big breakthrough in cancer detection and treatment. Our Woman’s Appeal aims to raise much needed funds for research into common women’s cancers, including breast, cervical and ovarian cancer. You can make a donation today to help fund research for women with cancer.
Zoe takes on Mt Kilimanjaro for cancer research Posted on June 15, 2016February 25, 2018 by Carly du Toit “In October, I’ll be fulfilling one of my biggest dreams — climbing Mt Kilimanjaro. About six years ago I did some trekking in Nepal and Tibet, and because I’m such a beach girl I was really surprised by how much I loved being in the mountains. It gave me this unexpected sense of peace and inspired me to explore other places. I knew that when I did finally get the chance to turn my dream into a reality, I would be fundraising for cancer along the way. Cancer research is a cause that is very dear to my heart. I have witnessed many loved ones suffer from this disease, including my grandfather who passed away from bowel cancer 16 years ago. My Aunty is now fighting ovarian cancer as well. After two rounds of chemotherapy, we’re hopeful that it won’t progress. Despite what she’s going through, she still carries herself with such courage and grace and inspires everyone around her. Her son was diagnosed with leukaemia at just two years old and sadly lost his battle at seven. I was 14 at the time and I remember how brave he was, how little he complained, and how much I learned about the importance of living each day to the fullest. This is when I first realised that life is precious and not to be wasted. You only live once so you may as well make it count, which is why I thought; why wait any longer to cross Mt Kilimanjaro off my bucket list? I really love to travel and meet new people and see new cultures so this is the perfect opportunity. Africa is such a fascinating place to me and I’m really looking forward to being in nature, removed from all the distractions of daily life. The area looks so stunning, I’m hoping that I might get a glimpse of some of the ‘Big 5‘ in their natural habitat. I’m sure it will be challenging but I’m passionate about breaking down the limitations of the mind and living the life of your dreams. A few years ago, I was in a serious car accident that left me with injuries and for months I was bed ridden, so ever since then I love to challenge myself physically and mentally. I remember trekking in Tibet, over a pass at 5500 metres and feeling so sick that I wanted to give up. But I just kept putting one foot in front of the other and telling myself “you can do this, this is nothing compared to what you’ve been through before.” The sense of accomplishment at the end of the day was like nothing else. It showed me that we can do anything we put our minds to. I am so proud to be climbing for cancer research. With 1 in 3 people now being diagnosed with cancer, I believe anything we can do to stop cancer in its tracks is important. Having seen so many loved ones go through treatment I think the more we learn about the disease, the better treatment will become. My hope is that we can not only cure cancer but prevent it. In honour of those who have survived, who kicked cancer in the butt, to those who are currently fighting and to those who have lost their battle, I dedicate this climb to you. I know that all of you will be with me every step of the way.” – ACRF supporter, Zoe Trenwith Zoe is a yoga teacher and in the lead up to her climb, she will be hosting a 108 Sun Salutation Fundraising class in South Australia on June 17th. “As a yoga teacher, I knew that hosting a yoga event was one way I could do something to bring people together.” If you would like to support Zoe, or find out more about her yoga class, click here.
New research study explains how cancer cells resist treatment Posted on May 31, 2016February 25, 2018 by Carly du Toit Cancer researchers at grant recipient, Walter and Eliza Hall Institute (WEHI) in Melbourne have worked out how a new class of anticancer drugs kill cancer cells. The finding also helps explain how cancer cells may become resistant to treatment. Dr Zhen Xu, Professor David Huang, Dr Stefan Glaser and colleagues studied a class of anti-cancer drugs called BET inhibitors, which are considered promising new drugs for the treatment of blood cancers such as leukaemia and lymphomas. BET inhibitors reduce tumour growth by blocking BET proteins, a family of proteins that control whether genes are switched on or off. Although it has been known that BET inhibitors are effective at halting tumour growth, it has been unclear whether the drugs kill cancer cells outright. The research team found that when tumours are treated with drugs, some resistant cancer cells can survive and continue to grow, leading to disease relapse. In the process, they identified potential ways in which cancer cells may develop resistance to BET inhibitors. The experiments revealed that BET inhibitors principally act to kill cancer cells through the process of programmed cell death (apoptosis). For BET inhibitors to successfully kill lymphoma and myeloid leukaemia cells the presence of a protein called BIM, which brings on apoptosis, was critical. “We found that when apoptosis was impaired, for instance by the loss of BIM, the BET inhibitors were no longer effective,” Dr Xu said. “This suggests that cancer cells that acquire mutations in genes that drive apoptosis will lose sensitivity to BET inhibitors and thus will be able to survive treatment, leading to disease relapse.” Dr Glaser said that knowing how BET inhibitors worked could help researchers develop improved strategies for using these drugs to treat cancer. “Understanding how the drugs work gives us the opportunity to investigate new treatments, for example by using combination therapies, or altering the dosage and timing of treatment to prevent drug resistance from emerging,” Dr Glaser said. The original news post was published on the WEHI website. The Australian Cancer Research Foundation has supported the Walter and Eliza Hall Institute by providing three grants, totalling AUD 5.5million, towards cutting edge cancer research equipment and technology.
More genetic risk factors for endometrial cancer uncovered Posted on May 24, 2016March 19, 2018 by Carly du Toit Cancer researchers at ACRF grant recipient, QIMR Berghofer Medical Research Institute, along with research teams from the University of Cambridge and Oxford University, have discovered five new gene regions that increase a woman’s risk of developing endometrial cancer. Endometrial cancer affects the lining of the uterus. It is the sixth most commonly diagnosed cancer in Australian women, with nearly 2,500 new cases expected to be diagnosed in 2016. The study was led by the head of the Molecular Cancer Epidemiology laboratory at QIMR Berghofer, Associate Professor Amanda Spurdle, and has been published in Nature Genetics. Associate Professor Spurdle said the findings helped to paint a clearer picture of the genetic causes of endometrial cancer in women who do not have a strong family history of cancer. “Up until now, we have only known about four gene regions in women in the general population that contribute to the risk of developing endometrial cancer,” Associate Professor Spurdle said. “In this study, we have identified another five, bringing the total to nine. This finding doubles the number of risk regions we know of, and therefore significantly increases our knowledge of the genetic drivers of endometrial cancer.” The study also looked at how the identified gene regions might be increasing the risk of other cancers, and what the implications would be for the future treatment of endometrial cancer patients. Interestingly, several of the gene regions we identified in the study were already known to contribute to the risk of other common cancers. “As we develop a more comprehensive view of the genetic risk factors for endometrial cancer, we can start to work out which genes could potentially be targeted with new treatments down the track,” Associate Professor Spurdle said. “In particular, we can start looking into whether there are drugs that are already approved and available for use that can be used to target those genes. Our genetic findings may also be useful, together with our knowledge of other risk factors, to identify women at risk of endometrial cancer so they can be regularly checked and be alert to the signs and symptoms.” The Australian Cancer Research Foundation has supported QIMR Berghofer Medical Research Institute by providing three grants, totalling AUD 6.65million, towards cutting edge cancer research equipment and technology. The original news post was published on the QIMR Berghofer website.
The forever kind of friend Posted on May 11, 2016February 25, 2018 by Carly du Toit ACRF supporter, Brett will be participating in Perth’s Run for a Reason in memory of his best friend Steph. “Twenty years ago, at 18 years old, Steph and I met through a friend and grew close from that day on. We were quite similar – we both loved to socialise and have fun. We were always laughing and never took life too seriously. Her quick, witty humour was my favourite part about her. Throughout our years of friendship, I would have to say, she helped shape me into the person I am today. Just under two years ago, Steph found out she had bowel cancer. It was devastating news but we thought, since she was young, her chances of survival would be good. They weren’t. When the tests came in we were told she had stage four cancer and it had already spread throughout her body. Steph, being the trooper that she was, fought a hard eight months and went through 20 rounds of chemo before passing last year. And she did it all with the utmost grace, I will always admire that. I decided to raise funds for cancer research because I felt I had to do something to help. This is the first time in my life that something like this has happened. Before Steph, I’d never lost anyone close to me. I believe it’s so important to support cancer research. Cancer is such and cruel and unforgiving disease and until it affects you or a loved one, you don’t realise how important it is to improve early detection and treatments for patients. This is my first running event. Since Steph’s passing, I was looking for a way to play some part in raising money for cancer research and Run for a Reason seemed like the perfect opportunity. Thank you to all my generous friends and family who have been so keen to support me. I hope that, by sharing this story, I can encourage others to get involved and come together to help end cancer.” – Brett Stubbs-Mills, ACRF supporter If you would like to show your support for Brett, please click here.
Cancer research develops new drug to enhance cancer treatment Posted on May 4, 2016February 25, 2018 by Carly du Toit Cancer researchers at the ACRF grant recipient, Harry Perkins Institute of Medical Research have developed a new drug that could be used to repair blood vessel defects and allow for more targeted and effective cancer treatment delivery. Current treatments like chemotherapy and immunotherapy can struggle to enter a tumour because the blood vessels that fuel it have become malformed. Tumours require a lot of nutrients so many times this causes blood vessels to re-direct towards the tumour, leading to abnormalities in the vessels. The drug that was developed by Woodside Professor Ruth Ganss and her team discovered that smooth muscle cells that line blood vessels to give them shape and help them pump blood often break down in tumours. Once the smooth muscle cells break down, the blood vessel becomes leaky, reducing blood flow and preventing chemotherapy and immune cells from travelling into the tumour. Professor Ganss said the new drug works by repairing the smooth muscle cells and returning normal blood flow to the vessels, allowing anti-cancer drugs to reach the tumour’s core. “To achieve greater absorption of anti-cancer drugs, the blood vessels are really key,” Professor Ganss said. “Helping stem the spread of cancer.” Professor Ganss said the defect in smooth muscle cells lining blood vessels in cancer could also be a catalyst for the cancer to spread. “It could be that once the smooth muscle cells break down and the blood vessels become leaky, cancer cells are able to slip out of the tumours and migrate through the bloodstream to spread to different parts of the body.” “We are currently investigating whether our drug could help stem the spread of cancer in a patient by repairing the leaky blood vessels.” The original news article was published on the Harry Perkins website. The Australian Cancer Research Foundation has supported Harry Perkins Institute of Medical Research by providing two grants, totalling AUD 3.6million, towards cutting edge cancer research equipment and technology.
I’m still standing Posted on April 28, 2016March 19, 2018 by Carly du Toit “Ian and I will have been married for 46 years next month. We have spent very little time apart in those years. We have three adult children and four grandchildren. We both grew up in the country but spent some time in Brisbane before settling in the rural town of D’Aguilar, Queensland. On Valentine’s Day in 2004, a year after we moved, I found a lump and was diagnosed with breast cancer. I had to undergo a major operation and travel to the city for daily radium treatments. Not only did cancer have a physical impact on my body, but it also affected me emotionally and financially. For a number of years after, I suffered panic attacks and became a recluse which made it incredibly difficult to work. Six years after my first diagnosis the breast cancer was back. Thankfully we managed to get through it all together. We never used to celebrate Valentine’s Day, but we do now because I am all clear and have been for six years now. However, our fight against this disease wasn’t over. A week before Christmas in 2014, Ian went to see the doctor in severe pain and he was diagnosed with pancreatic cancer. The doctors told him that unfortunately there was nothing they could do for him and that he should go home and get his affairs in order and enjoy what time he had left. After we had got all of our affairs in order, our son suggested we have a “wake” as Ian was always saying how unfair it was that you’re not there to party with your friends and family when you die. So we had a pre-departure wake last year. It was just what we both needed – over 120 people came and it was a fantastic day. During the day of celebrations, Ian told everyone to save the date for an ‘I’m Still Standing’ celebration in 2016 as he would still be here. And he was right. Because Ian was keeping well, his doctors did an endless amount of scans, blood tests, and biopsies and discovered that he had a Neuroendocrine Tumour. This is a slow-growing form of pancreatic cancer, but it is still terminal. It has been an endless roller coaster ride of emotions, with a lot of twists and turns, but we are grateful for this extra time to enjoy together. Cancer is an insidious disease that affects so many people. In the past five years, we’ve lost two brothers-in-law, I very recently lost my brother, and now I’m losing a good friend, and my husband – all to terminal cancer. I nearly lost Ian at Christmas this year, but the fantastic staff at the Redcliffe Oncology performed a miracle and like Ian had promised, he is still here. My darling Ian is such a fighter, so I have decided to make his “I’m Still Standing” celebration day into a fundraiser for cancer research. I wanted to make a difference and help the dedicated and hardworking researchers bring an end to cancer. We have been very humbled by the wonderful love and support of family and friends and even strangers. While I have been organising the fundraiser I have been blown away by people’s generosity. Thank you to everyone who has kindly helped this day come together. It’s going to be a fantastic event filled with lots of music, laughter, great prizes and everyone is welcome. We’ll also hold an auction, a cut and colour for cancer and have an open mic for anyone who wants to sing on the day. I would really encourage others to donate or fundraise for cancer research because you may one day help save someone you love! I hope that maybe our story will give someone else some comfort in their own struggle with cancer.” ACRF supporter, Carol Robinson
Australian melanoma rates improve Posted on April 13, 2016March 19, 2018 by Carly du Toit A study found that rates of invasive melanoma, the deadliest form of skin cancer, have started to decline in Australia and are predicted to keep falling over the next 15 years. Researchers at QIMR Berghofer Medical Research Institute have found that Australia no longer has the highest per capita rates of invasive melanoma in the world, after being overtaken by New Zealand. Researchers compared the rates of melanoma in six populations over a 30-year period from 1982 to 2011. The six populations were Australia, New Zealand, the United Kingdom, Norway, Sweden, and the caucasian population of the United States. The researchers found that melanoma rates in Australia increased from about 30 cases per 100,000 people in 1982 and peaked at nearly 49 cases per 100,000 people in 2005. The rates then declined to about 48 cases per 100,000 people in 2011. Invasive melanoma rates in New Zealand reached about 50 cases per 100,000 people in 2011. Professor David Whiteman, who led the study, said Australia was the only one of the six populations where melanoma rates had begun to fall overall. “We think the main reason for this decline is that Australia has put a huge effort into primary prevention campaigns since the 1980s,” Professor Whiteman said. “Australians have become more ‘sun smart’ as they have become more aware of the dangers of melanoma and other skin cancers. Schools, workplaces and childcare centres have also introduced measures to decrease exposure to harmful UV radiation.” “This has contributed to a decline in melanoma rates in people under the age of about 50.” “Unfortunately, rates of melanoma are still increasing in people over the age of about 50. This is probably because many older people had already sustained sun damage before the prevention campaigns were introduced, and those melanomas are only appearing now, many decades after the cancer-causing exposure to sunlight occurred.” Despite the fall in average melanoma rates per 100,000 people, the overall number of invasive melanomas diagnosed in Australia is still rising and is expected to increase from 11,162 cases per year from 2007-2011, to 12,283 cases per year from 2012-2016. Professor Whiteman said this was due to the ageing of the Australian population, as well as overall population growth. “Melanomas occur most commonly in older people. As Australia’s population ages, the number of melanomas diagnosed will continue to increase,” he said. “The picture in Australia at the moment is mixed. While it’s good news that average melanoma rates have started to fall, the fact that the actual number of cases is still rising is bad news.” The Australian Cancer Research Foundation has supported cancer research at QMRI Berghofer by providing three grants, totalling AUD 6.65million towards cutting edge cancer research equipment and technology.
Mark’s eyes are on the finish line Posted on April 8, 2016February 25, 2018 by Carly du Toit “I am 44 years old and have lived in Australia now for over 10 years. Last year, I had a very big scare when I was diagnosed with kidney cancer and had to have my kidney removed as a result. Discovering the cancer was completely incidental. I had no symptoms or impaired renal function. About eight months ago I was admitted to the hospital with lower bowel pain. The doctors performed a CT scan and found that I had colitis. They also noticed something that looked like a cyst in my right kidney. They advised me to get it investigated further so a few weeks later I had another scan. The result came back as “consistent with a cystic renal cell carcinoma.” It was in the very centre of my kidney. It was just two months from when we first saw the mass, to when I underwent surgery to remove my whole kidney. In that time the mass had doubled in size and the final pathology found that it was a grade 2 cystic renal cell carcinoma. Whilst I have enjoyed a good recovery and my prognosis is very good, there are many people and families who are not so fortunate. We need better diagnosis and treatments to help battle this terrible illness that has struck down so many of our loved ones. To help raise funds for cancer research, I decided to run in the Australian Running Festival’s Canberra Times half marathon. In 2015, I participated in the half marathon to prove to myself that I could still be healthy and active after a spinal fusion I’d had a few years earlier. This year I’ll be motivated to raise funds for cancer research, not only because of my own battle but for all my family and friends who have battled cancer, many of whom have sadly passed away. I want to try for a personal best but I have had to make big changes to my training. The biggest being that that I have only had eight weeks to prepare. Prior to that, I was not allowed to do any exercise, as I had to allow the stomach muscles to completely heal. It will make this year’s half marathon very challenging for me but running is not just about the physical activity, it also takes mental endurance. I hope that we can encourage more people to support cancer research so that the teams of scientists – the unsung heroes in this battle, can achieve breakthroughs that save lives. Thank you to everyone who has helped and supported me over the past six months as I have recovered and to those who have so generously donated to my page.” – ACRF supporter, Mark Potten. To support Mark’s fundraising page, click here.
New Sydney cancer research centre looks into metabolic causes of cancer Posted on March 31, 2016February 25, 2018 by Carly du Toit The Centenary Institute, in partnership with the Australian Cancer Research Foundation (ACRF) and Sydney Catalyst, today opened the new ACRF Centenary Cancer Research Centre at the University of Sydney’s Charles Perkins Centre in Camperdown. The new centre will focus on two key specialist areas of cancer research – understanding the inflammatory and metabolic causes of cancer and the drivers behind cancer-driven blood clotting. By investigating these two areas, the research team hopes to unveil how changes in metabolism support cancer growth and how these changes can be controlled by new treatments and therapies. The ACRF Centenary Cancer Research Centre will be headed by Professor Philip Hogg, a world-renowned researcher whose expertise lies in the discovery of new cancer-active drugs and therapies. The centre will host a team of over 40 dedicated cancer researchers whose capability spans fundamental research to clinical trials. “I would like to thank ACRF and their supporters for funding the new centre. It will significantly expand the Centenary Institute’s capabilities in cancer research and accelerate the development of new treatments for cancer patients,” said Professor Hogg. “Having this new facility has also helped us attract a brilliant team that includes some of the world’s leading scientific minds.” ACRF’s CEO, Dr Ian Brown said, “Supporters of ACRF helped lay the foundation for this centre, a centre that will help the team at Centenary reveal key information that will help inform better cancer treatments which is an exciting step forward.” The new centre is located within the University of Sydney’s Charles Perkins Centre and is the first dedicated cancer research centre in the Royal Prince Alfred (RPA) Hospital and The University of Sydney Precinct. The establishment has been a collaborative effort lead by the Centenary Institute and included the Australian Cancer Research Foundation, Sydney Catalyst, Sydney University, the Charles Perkins Centre, RPA Hospital and Chris O’Brien Lifehouse. Image from left: ACRF Chairman Mr Tom S Dery AO, NSW Minister for Medical Research, The Hon. Pru Goward, MP, Centre Director Professor Philip Hogg and Executive Director Mathew Vadas AO.
Shave to Save supports cancer research Posted on March 22, 2016February 25, 2018 by Carly du Toit Young Western Australian siblings, Prem and Mansi Aghera, together with their friends, Amee Bhuva and Ravi Ghodasara, raised over $6,000 for cancer research. We spoke to Prem about their amazing ‘Shave to Save’ fundraiser. “My sister, Mansi was affected by cancer some time ago, so cancer research is a cause close to home. Mansi wanted this fundraiser to be a tribute to those who aren’t as lucky as her and to help researchers bring an end cancer. We know first-hand how cancer affects patients and their families and we wanted to help prevent more families from going through what we had to. Apart from raising money, we also thought it was equally important to show solidarity with current cancer patients. We know that sometimes patients who lose their hair feel embarrassed and try to cover up. We hoped that by shaving our heads and proudly strutting around with our new looks that we could encourage people going through treatment to feel confident, with or without hair. We wanted to spread awareness of the importance of cancer research and get as many people involved as possible. By choosing to shave our head we attracted a lot of interest in our community. The ‘Shave to Save’ fundraiser was our way of showing everyone who is battling this disease that our community is standing with them – and we were overwhelmed by the support. Honestly, I don’t know why we didn’t do this sooner! We are truly humbled by the incredible support we’ve received over the past few months and we hope we’ve made a positive impact. We chose to support the ACRF because the main aim of the foundation is to eradicate cancer altogether, and that’s our ultimate aim too. While there is a long road ahead, we have seen the impact a small fundraiser can have. I believe that if people unite together we will continue to get closer to a future without cancer.” – ACRF supporter, Prem Aghera
FDC conquered the Rottnest Island Swim for Cancer Research Posted on March 18, 2016February 25, 2018 by Carly du Toit Thank you to our corporate supporters, FDC! A team from the Western Australian construction business took on the 19km Rottnest Swim challenge late last month. Their swimmers – Mark, Monique, Sveta and April along with support crew Ed, Jason and John were all very excited to be fundraising for a cause close to their hearts. “A number of people in our office have recently been touched by different types of cancer. So we chose to compete in this challenge to support the Australian Cancer Research Foundation because they are committed to ending all types of cancer. We received wonderful support from our work colleagues, friends, families and extended community. We encouraged everyone we knew to get behind our team and help us reach our target by donating their spare change or coffee money to cancer research. Together we were able to raise close to $3,000 for a charity we value so highly. The highlights on the day were all of us working together and having a laugh, everyone was very supportive – team members and competitors alike. This made our experience very enjoyable and we have been talking about doing the race again next year. Most of us know someone that is either fighting cancer or has been directly affected by it in one way or another. With the shocking stats out there we are proud that we could do our bit to help researchers find a cure for all cancers.” – ACRF supporter, April Moir To support the team, visit their everyday hero page. Photo supplied by Aussies in Action.
A motorcycle trek in memory of two great men Posted on March 16, 2016February 25, 2018 by Carly du Toit ACRF supporter, Daniel Kranz is a 36-year-old father of two. He lives with his wife, Hannah, in Tinonee. In addition to recently starting his own skateboard manufacturing business, he is also busy planning an epic postie trek to honour two special men whom he lost to cancer. “The Jindaboonda Postie Trek is a motorcycle ride of over 3,000km to raise funds for cancer research in memory of Dennis Jeffers (Jindaboonda). Last year pancreatic cancer took this awesome husband, father, son, grandfather, uncle and mate away from us. And what’s worse is Den wasn’t the first person I’ve lost to cancer. In 2001, I lost my Grandad, Murray Kranz, to leukaemia. Den and I were always trying to organise a ride together but unfortunately that never happened. Losing him so suddenly left our family utterly shell-shocked. I wanted to make something positive out of something so negative and organise this epic ride to celebrate the memory of him, my Grandad and everyone else who is afflicted by cancer. And what better way to help a family heal, than to get everyone together doing something these men loved, and in the process raise funds to help fight the disease that took them away. A love of motorcycling wasn’t the only similarity between Den and Murray. They were both devoted family men who were respected and adored by everyone that knew them. We are told time and again by numerous people how positive their impact was on the community and how dearly missed they are. They were fine examples of how to be a good human being. Both men were also very passionate about their careers. Den was an ecologist and ‘Jindaboonda’ was the name given to him by the members of the Biripi community after he worked with them extensively, teaching them about native plant seed propagation and bush regeneration. Murray was a mechanic and in his retirement he restored several old 40s and 50s motorcycles. I guess once motorcycling is in your blood – you’re hooked for life. Anyone who rides a motorcycle will agree with me that it’s about as close to complete freedom as you can get. Over 20 riders have registered for the trek so far. A large crew of extended family and close friends will also be following in support vehicles. I think all those postie bikes riding in group formation through town should get quite a lot of attention for the cause! We’ve even had a few people who obtained their licences just to take part in the trek. One such rider is Emma. She lost her mum to cancer three and half years ago, and there was no way she was missing out on doing the ride. We chose to support the Australian Cancer Research Foundation because it was important to us that we raise funds for an organisation that contributes to the research of all forms of cancer. When we approached the ACRF, they were so helpful and assisted me to get the ball rolling. It’s been a positive experience right from the start. We’re all working hard to fundraise as much as we can in the memory our loved ones, and in the process, we’re having an adventure and healing together. Thank you to all the participants, to everyone who has donated and sponsored us, and to all those who have helped us out so far.” – Daniel Kranz, ACRF supporter. To support the Jindaboonda Postie Trek, click here.
Melbourne researchers trial new leukaemia treatment Posted on March 8, 2016February 25, 2018 by Carly du Toit In a world-first clinical trial, Melbourne medical researchers have shown that patients with an advanced form of leukaemia can achieve complete remission with a new tablet treatment.The trials were conducted at The Royal Melbourne Hospital and the Peter MacCallum Cancer Centre, in collaboration with the Walter and Eliza Hall Institute, as well as trial sites in the US. Clinical trials of the potent new anti-cancer drug Venetoclax showed it was effective in killing cancer cells in people with advanced forms of chronic lymphocytic leukaemia (CLL) when conventional treatment options had been exhausted. Seventy-nine percent of those involved in the trial had promising responses to the new therapy – including twenty percent who went into a complete remission. A small number of patients had such a profound response that even very sensitive tests were unable to detect any remaining leukaemia in their bodies. CLL is one of the most common forms of leukaemia, with around 1,000 people diagnosed with this type of cancer in Australia every year. More than 350,000 people were estimated to have been diagnosed with leukaemia in 2012 worldwide, with incidence rates varying across the world. The drug has been granted priority review status by the US Federal Drug Agency (FDA) for treating some types of CLL. The designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. Venetoclax was developed based on a landmark discovery made in the 1980s by Walter and Eliza Hall Institute scientists that a protein called BCL-2 promoted cancer cell survival. Venetoclax was co-developed for clinical use by US pharmaceutical companies AbbVie and Genentech, a member of the Roche Group, and was discovered as part of a joint research collaboration that involved Walter and Eliza Hall Institute scientists. Professor Andrew Roberts, a clinical haematologist at The Royal Melbourne Hospital and cancer researcher at the Walter and Eliza Hall Institute, said the drug works very specifically by overcoming the action of BCL-2. “Most trial patients responded positively to the therapy, showing substantial reductions in the number of leukaemia cells in their body. Many patients have maintained this response more than a year after their treatment began, and some patients remain in remission more than four years on,” Professor Roberts said. “High levels of BCL-2 protect the leukaemia cells from dying, so leukaemia cells can grow and become resistant to standard treatments. Venetoclax selectively targets the interaction responsible for keeping the leukaemia cells alive and, in many cases, we’ve seen the cancerous cells simply melt away.” Professor John Seymour, Chair of the Haematology Service at Peter MacCallum Cancer Centre says, “The fact that a targeted drug, given on its own, can produce such a profound reduction in the leukaemia burden in the patient, to the point we cannot find leukaemia cells even with our best tests, underscores what a powerful strategy targeting the BCL-2 gene is.” These results set the foundation for building towards the dream of a cure for CLL. Phase 2 and phase 3 studies are currently being undertaken to test Venetoclax across a range of blood cancers globally, including at many sites in Australia. The Australian Cancer Research Foundation has supported cancer research at Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre by providing three major grants to both institutions, totalling AUD 12.5m. This news was first published on the Peter MacCallum Cancer Centre website.
Basia and Gary’s Story Posted on February 15, 2016February 25, 2018 by Carly du Toit “I was pacing the lounge room floor feeding Grayce when I heard a car door slam out the front. Just for a second, I thought he’d come home, that he had been out for dinner with the boys, that the last six months had disappeared. It felt nice, for one second, like it used to be. I hope there are other fleeting moments like that. Because just for a second, I was in that other life and I remembered how it felt to be happy. I lost my husband, Gary, to oesophageal cancer 19 days after we were married. Our third child, Grayce, was born four weeks later. Though our time together was short we managed to fit a lot of life into those years. We also had lots of quiet moments, just enjoying spending time with each other. He was very hands-on around the house and with the children. There was nothing he loved more than to potter around on the weekends doing the jobs he had listed during the week, fixing things and finding better ways of doing things and then we would have our coffee mid-morning sitting in the backyard. We would email each other every day at work – just a few words here and there, or an interesting article. I miss all the little things that made our lives so much fun. The touch of his skin, a thousand gestures. Gary’s battle with cancer started on the 2nd of July and lasted for twelve and a half weeks. As the cancer ate away at Gary, I thought he looked more beautiful. His spirit, grace and dignity shone through more with each passing day. He was the perfect patient. He never complained and would try and help me help him as much as possible, even trying to lift and move his legs with his hands, and I would tell him off each time. That’s why we decided to call our daughter Grayce with a ‘y’ – grace for how much of it shone through him during this battle. The four letters of Gary’s name are carried on in the name of his daughter. That was his next goal, and what he told the doctors at his last oncology appointment. He wanted to meet his daughter. In the end I couldn’t ask it of him. I knew he could hear everything I was saying. I lay down on the bed next to him and put his right hand on top of my belly. I told him I loved him so. I said, ‘I don’t want to let you go but I have to. It’s time for you to go.’ He opened his eyes and deliberately blinked at me for the first time in hours. Then he took two more breaths and went. I still cannot bring myself to stretch out across the whole bed. It will mean finally admitting to myself that he won’t be riding his bike home and pushing it through the open door. That he won’t be bending down to hug the kids as they come running to greet him, squealing with delight. I know those things cannot happen but I still see them. I wish them. I live them in my head. They say memories are golden. Well maybe that’s true, but I never wanted memories, I only wanted you.” – ACRF Supporter, Basia We can’t bring Basia’s husband back to her but we can stand beside her while she continues to battle cancer through supporting research. To help her in her mission to protect others from having to go through what she went through click below. DONATE NOW
A little girl with big dreams Posted on February 2, 2016March 19, 2018 by Carly du Toit At only seven years old, Leah Paterson is one of the Australian Cancer Research Foundation’s youngest supporters. She’s been working to raise funds for cancer research in honour of her great-grandmother who is currently undergoing treatment for pancreatic cancer. Leah has earned a place as a finalist in the Junior Miss Diamond Australia 2016 pageant. The contest encourages participants to be part of a cause that helps others and teaches them how to fundraise for charity. As part of her quest to gain the title, Leah is required to represent her local area and choose a charity to partner with. Leah chose to support cancer research through the ACRF as her family has been touched by the horrible disease twice in the past few years. “My great-grandmother has been going through treatment for pancreatic cancer. And my mum also lost her uncle a few years ago to the same cancer. I am raising money so researchers can help fix people like my great-grandma by finding stronger ways to fight cancer,” said Leah. Leah is hoping to raise close to $2,000 before the pageant grand final in April. To help reach her target she been raising awareness about cancer research by doing various fundraising activities throughout her school and community. Leah’s mother and great-grandmother are very proud of Leah’s commitment to a cause so close to their hearts. “This contest is different to typical pageant competitions, it focuses on promoting community values and helps teach children that there is so much more to beauty than physical appearance,” said Leah’s mother, Sara.
Fighting blood cancers with new therapies Posted on January 29, 2016March 19, 2018 by Carly du Toit Researchers at the Peter MacCallum Cancer Centre in Melbourne are pioneering the development of a new combination drug therapy to treat advanced blood cancers. The new therapy builds on a world-first clinical trial already underway at Peter Mac, which uses the drug CX-5461 to treat patients with incurable blood cancers such as myeloma, lymphoma and leukaemia. The new discovery, published in the journal Cancer Discovery, has shown promising results to date. The research team has found that CX-5461 could be even more effective when used in combination with another drug, Everolimus, already used to treat other cancers. The new combination has shown doubled survival times in pre-clinical laboratory models. According to Professor Rick Pearson, Head of Peter Mac’s Cancer Signalling Laboratory, the research findings significantly enhance understanding of pre-emptive strategies to kill off cancer cells before they have the chance to become resistant to therapy. “CX-5461 targets a particular process that is required for cancer cell survival. Our experiments show that adding Everolimus synergistically strengthens this attack, more rapidly and more effectively eradicating the killer disease.” “We know that all cells rely on ribosomes (protein builders of the cell Ed.) which act like a factory producing the proteins essential for their growth and survival,” said Professor Pearson. “Peter Mac researchers have previously shown that certain blood cancers are far more reliant on these proteins than normal cells and that eliminating the protein production capability of ribosomes leads to the rapid death of cancer cells while normal cells stay viable.” “This novel therapy works to inhibit the ribosomes’ protein production capability, effectively starving the cancer cells of a key ingredient they need to survive and proliferate.” “A further study in collaboration with scientists at Monash University shows striking effects in the targeting of late stage prostate cancer through a similar strategy indicating that this approach may be generally applicable for a range of cancer types.” Associate Professor Simon Harrison, Consultant Haematologist at Peter Mac and Principal Investigator on the CX-5461 first-in-human trial, says this new research provides further confidence that researchers are on the right track. “The prevalence and poor prognosis for people with advanced blood cancers demand the ongoing and intricate study of abnormal cell behaviour, which has been an indicator of cancer for over 100 years. To date, 15 patients have been treated on the first-in-human clinical study with a number of patients experiencing prolonged benefit.” More than 12,000 Australians are diagnosed with blood cancer annually (approximately 10% of all cancers) and around 4,000 Australians will lose their lives to the disease each year. This research is supported by the National Health and Medical Research Council; Cancer Council Victoria; the Leukemia Foundation; Prostate Cancer Foundation of Australia; Cancer Australia; Victorian Cancer Agency, Australian Cancer Research Foundation and Peter MacCallum Cancer Foundation. Collaborators include the John Curtin School of Medical Research at the Australian National University and Monash University. The Australian Cancer Research Foundation has supported cancer research at Peter Mac by providing three major grants, totalling AUD 7 million. The news was originally published on Peter Mac’s website.
Toby’s Beard Shave for Cancer Research Posted on January 20, 2016February 25, 2018 by Carly du Toit “My name is Toby and I’m 29. I was diagnosed with rectal cancer in October 2014. Prior to my diagnosis, I was a very active and healthy person – I enjoyed running and hitting the gym, I never smoked and drank only on occasion. There was also no history of rectal cancer in my family – so the diagnosis came as quite a shock. Since then I have received multiple rounds of chemotherapy and radiation, as well as some major operations so doctors could remove the cancer, create a temporary ileostomy, and then reverse it. I’m currently recovering from the reversal surgery and getting used to my new “plumbing.” I will still need to go to follow-up appointments every three months or so but fortunately I was given the all clear late last year. A couple of months before I was diagnosed I started growing a beard. Once everybody got over the initial shock of my diagnosis, questions began turning to my beard and when I was going to shave it. My beard had become a comfort for me through all of this, so if I was going to shave – it had to be for a good reason! I started thinking about the idea of shaving it off for charity and because I received so much support, I felt that I should do something to give back. Cancer is too common and this has become even more obvious since I was diagnosed. Almost everyone I meet has a story of someone close to them who has been affected by cancer. I feel like I am one of the lucky ones and I wanted something good to come from my experience. On Australia day, I’ll be holding a celebration and shaving ceremony at our local bowls club. I’ll be putting on a big barbeque to say thank you to all my friends and family who supported me and donated to my cause. I’ll also be raffling off some great prizes from generous local businesses, as well as the honour of who will get to make the first cut of the shave! I really hope that someday, no one will have to go through what I and so many others have been through. Finding a cure or a gentler form of treatment is the ultimate goal and that is why I decided to support the Australian Cancer Research Foundation. Every little bit helps to bring us closer to finding a cure or developing better treatments that will make it easier on those diagnosed, and their family.” – ACRF Supporter, Toby Stodart. To support Toby’s Beard Shave for Cancer, click here.
Breakthrough in predicting the spread of cancer Posted on January 14, 2016February 25, 2018 by Carly du Toit A team of cancer researchers from Australia and the UK have bred a biosensor mouse that has enabled them to watch as pancreatic cancer cells ‘unzip’ right before they begin to spread. “Our biosensor mouse makes it possible to look at a primary tumour that has not yet spread: in real time, in 3D, and in a living tumour. Using state-of-the-art laser technology, we can see, at a molecular level, whether the contacts that hold tumour cells in place have started to unzip – and that’s a sign that the cancer is about to spread,” says Dr Paul Timpson of Sydney’s Garvan Institute of Medical Research. To understand how unzipping contributes to the spread of pancreatic cancer, the researchers implanted a genetic model of invasive pancreatic cancer. Remarkably, the researchers were able to successfully rezip these cancer cells by treating them with anti-cancer therapies, stopping the spread of cancer before it had begun. To make the biosensor, the researchers bred a mouse in which a key “zippering” protein that holds cells together – called E-cadherin – was linked to a protein from jellyfish that glows green in fluorescence microscopy. This allowed for them to pinpoint when key changes occured. Which is incredibly important given that five-year pancreatic cancer survival rates stand at just 6.1% – a figure that has barely changed in the last 40 years. “Many patients present with pancreatic cancer at a very advanced stage, when the cancer has already spread to other tissues such as the liver,” says Dr Timpson. “But sometimes, the cancer is detected before it has spread – and that’s the point where we have an opportunity to intervene and stop it in its tracks. If we give a drug early enough, we can rezip those cells together.” Dr Timpson says the most exciting part of the study was the fact that the existing treatment – an anti-invasive drug called dasatinib – allowed us to stabalise the primary tumour. “We treated mice that had developed pancreatic cancer that had yet to spread with the anti-invasive drug [and] within three days of treatment, we saw cells within the tumour had re-zippered, and the tumour had stabilised.” Similar results were achieved with a second therapy, saracatinib. “The biosensor mouse is a powerful tool for anti-cancer drug discovery,” Dr Timpson says. “It makes it possible to evaluate the effect of new therapies on tumour spread, in real time and in a system that reflects human cancer as closely as is currently possible.” Dr Timpson points out that this is just the beginning for the biosensor mouse. “We now have a model that is one step ahead of the invasion process in pancreatic cancer – but we are also already using this model in our laboratory for other aggressive and highly invasive cancer types, such as breast cancer. “Ultimately, we expect to use the biosensor mouse to explore zippering and cancer spread in a wide range of tumours throughout the body.” The Garvan Institute of Medical Research has received three ACRF cancer research grants totalling $6.13m. To read the original article, click here.
I’m a walking testimony to cancer research Posted on January 7, 2016February 25, 2018 by Carly du Toit Pamela Kirby supports cancer research because she has seen the life-saving benefits first-hand. “My cancer journey started in September 2010. I was first diagnosed with bowel cancer and an operation was quickly scheduled for November. It was during my treatment process that I was also diagnosed with stage 1 primary lung cancer. Within a few weeks I was back in surgery for a major lung cancer operation. That was the hardest to recover from and it was followed by four and a half months of chemotherapy treatment. Unfortunately, the bad news continued and in 2013 three more lesions were discovered on my lung. By May 2014 I had suffered a major seizure and my doctors told me I had developed secondary brain cancer that spread from my lungs. Cancer has been a challenge from day one, but it has been really empowering to fight this battle and I believe I am much stronger now. After five years of intensive treatment and lengthy hospital stays, the prognosis is looking good for me and I’m feeling much better. I am so thankful for my highly skilled oncologist Dr Nick Pavalakis and his team. Using the treatment options and testing resources cancer research has made available to them, they were able to learn more about my cancer, find out which treatments would work best for me and help manage some of the unbearable side-effects. From my experience I learned just how vital cancer research was and how significantly it impacts current patient treatments. I’m a walking testimony to the progress researchers are making. Whilst undergoing treatment I wanted to inspire others affected by cancer and show them that they have the strength to fight through this battle too. I decided to organise a fundraising event to help contribute towards cancer research. I held a Ladies Night Out at our local bowling club. It was a great evening of tequila tasting, 60’s music, a fashion parade, raffles, candle demonstrations and an auction. I’m really proud that we were able to raise close to $4000 for the Australian Cancer Research Foundation. My health has greatly improved and we’re now looking forward to the future and a special holiday in Hawaii in just a few weeks. I still need to get scans every three months, which are stressful as waiting for the results is always a torment. But I believe remaining positive has really helped me on this journey and I am thankful to have been supported by my wonderful friends and family and a highly skilled medical team. Every new day I get to spend with my amazing husband Brian, our kids and grandkids is sheer joy.” – Pamela Kirby, ACRF Supporter Share your story
Australian Cancer Research Foundation gives $17 million to advance cancer research Posted on December 9, 2015March 13, 2018 by Carly du Toit The Australian Cancer Research Foundation (ACRF) announced its 2015 grant recipients at an awards ceremony in Sydney last night. This included one of the largest private grants for cancer research equipment in Australian history, the $10 million ACRF 30th anniversary grant. The anniversary grant was awarded to The Children’s Medical Research Institute based in Sydney, for the establishment of The ACRF International Centre for the Proteome of Cancer (ProCan). This facility will enable the analysis of tens of thousands of samples of all types of cancers from all over the world. It will also allow scientists in Australia to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide. The end result will be rapid and more accurate development and initiation of the most appropriate cancer treatments for each individual patient. “Our 30th-anniversary grant for $10 million is something ACRF is very excited about,” said Professor Ian Brown, CEO of ACRF. “We knew this amount of money could make a real difference, stimulate new ideas and bring us closer to ending cancer.” “ACRF challenged the Australian cancer research community to propose projects that were bold and that would have a very significant impact on cancer prevention, detection and treatment. The response was tremendous with six very impressive projects submitted.” Our international judges were impressed both by the quality and vision of the applications and the high standard of Australian research. CMRI was chosen after lengthy discussion to be the best of the best.” In addition, Cancer Institute NSW will be supporting the project by funding a full time researcher at CMRI to operate the new technology. The recipients of the annual ACRF grants in 2015 are: The Australian Synchrotron ($2million) for the establishment of the ACRF Detector. The technology, which is available at only a handful of other synchrotron facilities around the world, will enable the shape and function of proteins to be analysed ten times faster, and more accurately, shortening the timeline from laboratory research to clinical trials of new cancer drugs. The John Curtin School of Medical Research, ANU ($2 million) for the establishment of the new ACRF Department of Cancer Biology and Therapeutics. The department will help to understand the underlying biology of cancer and to develop new drugs to treat Australian cancer patients. Research will focus on Australia’s Chmome (whole sets of small molecule natural products) and exploring the existing collections for novel lead compounds that can be developed into drugs for cancer therapy. The Centre for Cancer Biology (CCB) in South Australia ($2 million) for the establishment of the world-class ACRF Cancer Discovery Accelerator facility in Adelaide. The centre aims to significantly enhance our understanding of fundamental cancer biology and translate these findings to improve outcomes for Australian cancer patients. University of Queensland, Thoracic Research Centre ($1million) for the establishment of the ACRF Centre for Lung Cancer Early Detection. The Centre will conduct research into the discovery and development of innovative methods for detecting lung cancer as early as possible. Lung cancer remains a major worldwide cause of cancer deaths, and early detection will improve treatment outcomes and survival rates. The recipient of 30th-anniversary grant was selected by an international judging panel after a competitive application process. The four annual grant recipients were selected by the ACRF’s Medical Research Advisory Committee comprising eminent Australian and international cancer researchers and clinicians, chaired by Professor Ian Frazer.
Fighting cancer with fitness Posted on October 30, 2015March 13, 2018 by Carly du Toit In April, dedicated ACRF supporter, Jodie Gardiner ran in the Australian Running Festival in Canberra and raised over $2,200. Now she’s working her way through a unique fundraising challenge she set for herself called ‘Fighting Cancer with Fitness.’ Jodie hopes to complete 100 workouts before her 42nd birthday while raising funds for a cause close to her heart. “This year I lost my step-sister, Rachael to liver cancer. My step-mum was diagnosed and is fighting lung cancer. My aunty was diagnosed and is fighting breast cancer. Last year I also lost my uncle to cancer. This is an insidious disease and I’ve had enough. In losing my step-sister Rachael, we didn’t just lose one woman we lost several because she was the center of so many universes. We always got on like a house on fire and shared a lot of similarities in our lives – we were both public servants who also qualified as a personal trainer and we each had two sons. Rachael was diagnosed with a rare form of liver cancer called Sarcomatoid Hepatocellular Carcinoma. After ten months of treatment, she lost her battle. She was only 36 years old, leaving behind her loving husband, Paul and their two young sons. Rachael was a great mother, it broke her heart that she would not be there to see her children grow up. She worried that her sons wouldn’t remember her, so she asked her family to promise to help make sure they would never forget her. Paul has been an absolute tower of strength for his sons and is making every effort to ensure they still see their grandparents and that they will always remember their mum. I am fortunate to have some great memories of Rachael. I worked at a gym with her a few years ago. We had an absolute ball working together – we learned so much about each other and became really close. Rachael was such a fun, energetic and vibrant woman. She had such a passion for health and exercise, and her love of fitness inspired me to get my personal training qualifications. I remember not long after Rachael was diagnosed, her sister Kylie was attempting her first 10km fun run. Rachael and her family were waiting on the sidelines to cheer Kylie on. Suddenly, Rachael ran out from the crowd to jog alongside her sister. Rachael motivated Kylie through the final kilometres and they crossed the finish line holding hands. It was a very special moment that I’m glad I got to witness and I think it beautifully sums up what sort of a person she was. Losing her to cancer made us all realise that life is short and it has certainly made us all stop and smell the roses a little. Everyone knows someone who has been diagnosed with some form of cancer, I’m fighting for all of them.” Click here if you would like to support Jodie. Share your story
Cancer Research to Benefit from Twitter for Cells Posted on October 13, 2015March 13, 2018 by Carly du Toit An international team of researchers have completed a study into cell behaviour, providing insight into how different, specialised cell types communicate as a cohesive network. The researchers have produced the first map of cell-to-cell communication which shows the division of labour between cell types and reveals the ways cells use proteins to pass hundreds of messages between each other. This will help advance cancer research in the future. The lead author, Professor Alistair Forrest, recently joined the Harry Perkins Institute of Medical Research in WA as Laboratory Head of Systems Biology and Genomics to continue his work with a renewed focus on cancer. Professor Forrest says systems biology studies all elements (typically genes or proteins) simultaneously to see how they work together in a system (or network) instead of focusing on only one or two genes at a time. “What we have revealed in this new research is that cells have many ways of talking to each other.” Imagine twitter for cells – hundreds of cell types telling each other what is happening via hundreds of different messages. Professor Forrest says the work has important implications for medicine. “The proteins involved are actually well known to the general public. Insulin, human growth factor and leptin are important in diabetes, height and obesity. This type of signalling is also very important in our immune response to infectious diseases. It’s also important in cancer – in particular neuroblastoma and lung cancer.” The researchers believe that further investigation will provide answers into what happens to this intercellular information in cancer cells and how cancer avoids the immune system. It is hoped that this research will eventually help identify new therapeutic targets to improve treatments for people battling cancer. The original article was published on the Harry Perkins Institute of Medical Research, click here to read more.
Beneath the surface of skin cancer patients Posted on September 16, 2015March 14, 2018 by Carly du Toit Here at the ACRF we are proud to equip Australia’s leading cancer researchers with the resources they need to end cancer. Recently, a team of researchers from the University of Queensland discovered a protein that helps to control an important process in cell adhesion that is disrupted when someone contracts a disease such as skin cancer. The researchers said that the Australian Cancer Research Foundation Cancer Biology Imaging Facility at UQ’s Institute for Molecular Bioscience (IMB) played a vital role in this research. It is currently one of the largest and most comprehensively equipped facilities in Australia for both the imaging and screening of chemical and biological libraries. The facility was founded in 2010 with a $2.5 million ACRF grant and is home to 23 high-performance microscopes and supporting image data analysis workstations. PhD student Rashmi Priya at IMB says that what the research has done is clarify the role of the protein myosin in tissue integrity. “The protein Myosin is found at cell connection points and we now know that it plays a crucial role in regulating how cells stick together to form tissues in the body,” she said. “Our research has shown that this is because myosin protects a switch that acts as a stabiliser. This switch must be very tightly controlled as it affects many processes within the body. Too much or too little of this switch, or having it in the wrong place, can lead to diseases such as skin cancer, says Priya.” Professor Alpha Yap, who led the research team, says “The cells in all the tissues of our body die and have to be replaced as regularly as every 24 hours in the intestinal system. For this to happen, adhesion between cells must be carefully broken down and rebuilt, and we now have a better understanding of what it is that’s controlling this whole process.” The original article was published on the Institute for Molecular Bioscience website, click here to read more.
Over $117,000 raised for cancer research at City2Surf Posted on August 12, 2015March 14, 2018 by Carly du Toit This past weekend over 80 thousand people participated in the iconic 14 kilometre City2Surf. Runners set off from Hyde Park in the heart of Sydney’s CBD and made their way through to the finish line at Bondi Beach. This year, Team ACRF was made up of 190 incredible runners from all walks of life. Thanks to their hard work and dedication they were able to raise over $117k for cancer research. Many of the ACRF runners have been personally affected by cancer, including Jonathan Wiener, who had an army of supporters contribute an astounding $20,000 in memory of his cousin Michelle, who lost her battle with brain cancer in February. “I promised Michelle that I would do everything in my power to find a cure for this devastating disease and running City2Surf for cancer research is my first step in keeping that promise.” Supporting them along the way were 35 enthusiastic volunteers who cheered on Team ACRF and doled out high-fives from the sidelines. One of ACRF’s Corporate Champions, Deloitte, generously sponsored a fantastic beach front Marquee where ACRF runners and their families joined the Deloitte team for a congratulatory lunch on the beach. The ACRF thanks everyone who participated in the City2Surf or who came out to support our runners on the day. We loved meeting you all and celebrating your achievement. View the team leaderboard – click here.
The moment that changed my family forever. Posted on July 14, 2015March 14, 2018 by Carly du Toit “Back in 1998 my husband and I were like any other typical family. We had two sons, one aged four and eight. My husband, Craig, was an electrical engineer and Officer in the Navy. He was passionate about the Navy and his job at HMAS Albatross in Nowra. Craig was looking forward to being promoted and taking the next step in his career, while I was studying adult education and both our boys were involved in many sporting activities. We were no different than any other family. April 1998 will be a month I will never forget. Craig had been complaining of not feeling well, having a sore throat and just feeling lethargic. Within one week Craig had been admitted to the oncology section of Wollongong hospital and diagnosed with a rare form of Acute Myeloid Leukaemia. Our world tipped upside down in a moment and I was trying to explain to a four and eight year old that their father was very sick and may not live. Craig was told that the only way he could live was with a bone marrow transplant and that he didn’t have much time. The chances of survival were given at 30%. Craig endured chemotherapy which was quickly followed by a bone marrow transplant. Fortunately for Craig his identical triplet sisters were a match and one was selected as his donor. Hurdle one was achieved. The next step was to get into Westmead Hospital for the transplant and that was hurdle two. The transplant unit only took 6 patients at a time and we had to wait. Unfortunately we didn’t have time to wait. Eight months were spent in and out of hospital however after the transplant it was found that Craig had suffered a complication from the transplant which affected his lungs. After many years with Craig’s lung problems he eventually passed away on 8 August 2002 at 38 years of age. Throughout all the treatments and hospital visits there was one thing that Craig was passionate about and that was raising funds to find a cure for leukaemia, particularly in children. Craig felt that if he found the treatments hard to cope with, then small children with any type of cancer would be in a worse position. I continue Craig’s passion for finding a cure for all cancers, which is why I have become a Partner in the Cure. The researchers and medical professionals working at ACRF are equally passionate about finding cures in the hope that people like Craig get to live a fulfilling life with their families. I’m proud to do my small part by regularly donating to the ACRF so that they can continue to fund breakthroughs in cancer research. Cures for cancer can only come from research and if we all contribute a small amount this means that cancer research can continue in Australia,” Regular Giver of the Month – Dianne King. Learn more about becoming a regular giver. Share your story
New discovery a sign of hope for melanoma patients Posted on July 10, 2015March 14, 2018 by Carly du Toit After four years of dedicated research, PhD student Mitchell Stark has made a remarkable discovery at the QIMR Berghofer Medical Research Institute, a facility which has been awarded three grants from the ACRF. He has uncovered new markers which will help increase the speed, accuracy and accessibility of tests that monitor the progression of Melanoma. Mr. Stark’s study has revealed that elevated levels of microRNA’s, which are tiny molecules that regulate the amount of protein in a gene, can indicate that the cancer is at risk of spreading. “They are highly sensitive and specific, and are significantly better than markers currently being used,” says Mr. Stark. “In specimens from stage IV patients, the new biomarkers confirmed tumour progression in 100% of cases.” Mr. Stark said this is significant because it will allow patients to start treatment before metastatic disease is clinically evident, which could greatly improve a patient’s chance of survival. “Patients with stage III melanoma, with spread confined to regional lymph nodes, have a five-year survival rate of about 50%, compared to less than 15% if metastases are widespread.” In addition to the accuracy, another positive is the method in which the testing is done. All that is required from a patient for the markers to be detected is a routine blood test. This will better identify the group of patients that require additional expensive and stressful tests such as CT scans. Queensland Science Minister Leeanne Enoch said the research represents a significant advance for melanoma patients. “This is an excellent example of the world-leading research at QIMR Berghofer which has the potential to make a real difference to the lives of patients in Queensland and around the world.” QIMR Berghofer Medical Research Institute has received $6.65 million in grants from the ACRF which has funded technology to progress research in colon, breast, ovarian, prostate, leukaemia, lymphoma and melanoma. The original article was published on the AIMR Berghofer Medical Research website.
Genetic sequencing in Australia could revolutionise cancer diagnostics Posted on June 12, 2015March 14, 2018 by Carly du Toit It is being called ‘the frontier of medical science”’. The potential to pre-empt cancer diagnosis with genetic testing has taken a major step forward following the first Australian NATA* accreditation for ‘whole exome sequencing’. SA Pathology’s Genetics and Molecular Pathology laboratory, in collaboration with the Centre for Cancer Biology’s ACRF genomic research facility, have received this important stamp of approval to test the complete set of human genes in a single assay, using cutting-edge Next-Generation Sequencing (NGS) Technology. Professor Hamish Scott, Director of the ACRF Cancer Genome Facility at SA Pathology’s Centre for Cancer Biology explains: “In human DNA there are six billion data points, 2% of them are our genes, which can be sequenced in an ‘exome’. We’re searching through over a hundred million bases to try and find an anomaly or a mutation that may be causing disease.” This landmark accreditation rewards many years of research dedication and collaboration between research and funding bodies, including the Australian Cancer Research Foundation. Dr Karin Kassahn, Head of Technology Advancement says, “With this new approach, genetic tests will take months, not years, and see an end to some of the uncertainty – there will be definitive results for more patients.” “These technologies weren’t available a decade ago, but now genomics is set to play a major role in medical treatment. If we get this right, genetic testing will become an integral part of health care, available to everyone in need.” Professor Scott has said that unfortunately many rare genetic conditions still don’t have an effective treatment or cure. “But if we can pick these things up, we may be able to alleviate symptoms with new therapies and help patients and families manage their disorders,” he said. “This is the future of healthcare, what’s known as ‘personalised’ or ‘precision’ medicine.” The ACRF is proud to have supported the world-class research teams at SA Pathology, Centre for Cancer Biology. We thank our donors and fundraisers for their dedication to cancer research, without which, this important progress would not have been possible. This information was originally published by SA Pathology and can be viewed here. *NATA is the National Association of Testing Authorities in Australia. It ensures facilities, testing and measurement methods comply with relevant international and Australian standards.
World-first research centre signifies a new era for cancer research Posted on May 22, 2015March 14, 2018 by Carly du Toit The Australian Cancer Research Foundation Telomere Analysis Centre officially opened its doors this week to become the world’s first facility to specialise in Telomere research. Recent findings argued a strong case for the development of this cutting-edge facility, indicating Telomeres could hold the answers to significant advancements in the treatment of some of the most aggressive types of cancer. Telomeres are structures that cap the ends of our chromosomes. They serve a critical role in the cell renewal process and under normal conditions, gradually shorten as we age. But studies at the Children’s Medical Research Institute have shown that cancer cells develop ways to disrupt this natural process. They re-program cells to prevent their telomeres from shortening, causing the DNA to “short-circuit” and cells to multiply out of control. Furthermore, researchers have found ‘lock’ mechanisms on normal cancer cells which prevent this process. The ‘lock’ on cancer cells, however, is damaged, providing researchers with a new target for treatment. CMRI Director, Professor Roger Reddel, who was involved in the research, said “We think that losing this lock makes cancer cells vulnerable to treatments that normal cells are protected against. So we may have found an Achilles heel for certain types of aggressive cancer.” “The ACRF’s Medical Research Advisory Committee assessed this research initiative as both nationally ground-breaking and internationally competitive. The ACRF and our supporters are very proud to fund this life-saving work at CMRI,” said ACRF Chief Executive, Professor Ian Brown. The new ATAC facility was funded with a $2 million ACRF grant and is outfitted with some of the most advanced technology and cutting-edge equipment that exist in this field. These microscopes and computer analysis stations provide speed and accuracy on unparalleled levels, helping to propel telomere-related cancer research to new heights and accelerate the race toward new treatments, and ultimately, cures for cancer.
A man honours his hero, best friend and father Posted on May 19, 2015March 14, 2018 by Carly du Toit “I have chosen to become a Partner in the Cure due to the recent passing of my father, Stan Phillips, at age 76. My father was a major influence on me and truly was a great man. He lived his life to the fullest and touched the hearts of many. He lived a long life, but for me his passing still came too soon, I was hoping he would be around longer to see his two grandchildren grow up. He was very fit and I think he would have had years left if it wasn’t for cancer. It was a shock when he had to be rushed to hospital and we discovered he had bowel cancer. He fought a hard battle for three years right up until he passed, and through it all he was positive, smiling and enjoying life. He was a real family man who put us first and was more concerned with my family than his own struggle. He worked hard to give us every opportunity in life and rarely treated himself. He was my mentor, training partner and best friend. The way he lived his life and fought cancer is why he is my role model; I will be happy if I can live up to just half of his standards and I hope I can pass this attitude to life onto my children. It’s amazing what a perfect father he was especially when he lost his own in the 2nd World War at the age of four. His determination in life led him to be successful in several different careers, starting out as a carpenter, then serving in the Elite Parachute Regiment, and finally becoming a construction site manager. He was also wonderful husband to my mother Margret. Today would have been their 50th Wedding Anniversary. Karate was one of his favourite hobbies. He trained for eight years earning his black belt in 1983 and only stopping a few months prior to his passing when he became too ill. The club he belonged to now awards a trophy in his name. He requested that people make donations to cancer research in lieu of bringing flowers to his funeral. He believed, as I do, that if we can contribute to the advancement for a cure it will one day save my children or grandchildren from this terrible disease,” Nathan Phillips. Share your story
Why do so many people run for a cause? One runner tells his story. Posted on May 7, 2015March 14, 2018 by Carly du Toit Today it seems that everyone (and their dog) is running a fun run, half or full marathon. But what the growing numbers don’t say is how hard it actually is to finish a race. They don’t tell you that there is something special you need, right out of the gate, in order to have a shot at finishing what you’ve started. You need something that will keep you going when your body is pleading with you to give up. For most, this will be a cause that is bigger than they are. For Jonathan Weiner it’s the thought of his cousin. Having lost Michelle to cancer, Jonathan became determined to do something to honour her memory and make a difference. It’s fuelled his fire to run in this year’s City2Surf in August. Jonathan says “I am going to keep a promise that I made her. I promised Michelle that I would do everything in my power to find a cure for this devastating disease, and this is my first step in keeping that promise.” “Although my cousin died of brain cancer, many different types of cancers have affected my family, which is why I chose to raise funds for the ACRF. It is a way for me to help fund research in all types of cancer,” says Jonathan. People from all over the world are joining forces to help Jonathan reach his goal of raising $18,000 for cancer research and support him in his journey to honour his cousin. To get behind Jonathan in his cancer fun run please click here. To see how you can embark on your own running challenge here. Share your story
New screening technique developed to detect ‘silent’ ovarian cancers early. Posted on May 7, 2015March 14, 2018 by Carly du Toit University of NSW Vice-Chancellor Ian Jacobs. Image source: UNSW Newsroom Ovarian cancer is often referred to as a ‘silent killer’, with around one hundred thousand women succumbing to the disease globally each year. Symptoms can be very vague, and the disease often spreads before the cancer can be found. But there is new hope for early detection. The latest results from a clinical trial led by UNSW Vice-Chancellor, Prof. Ian Jacobs, in collaboration with University College London, have shown a novel new screening method can identify twice as many women with ovarian cancer as existing strategies. The new screening programme allows researchers to better interpret the changing levels of a specific protein called CA125 (which has been linked to ovarian cancer) through a blood test, giving a highly accurate prediction of a woman’s individual risk. “The sensitivity is very, very high – much higher than people thought would be possible,” said Professor Jacobs. The new method detected cancer in 86% of women with invasive epithelial ovarian cancer (iEOC). Previous methods, which detected just 41%, would only raise concern once the concentration of this protein had passed a fixed threshold. The problem with this was that certain women with high levels didn’t actually have cancer, while others with levels below the threshold did. Professor Jacobs says, “What’s normal for one woman may not be so for another. It is the change in levels of this protein that’s important.” The trial involved over two-hundred thousand post-menopausal women aged 50 or over and was the largest of its kind to date in the world. “My hope is that when the results of UK Collaborative Trial of Ovarian Cancer Screening are available, this approach will prove capable of detecting ovarian cancer early enough to save lives.” Prof. Jacobs’ team are awaiting further test results later this year before the method has proved capable of detecting ovarian cancer early enough to save lives. If these results are positive, Prof. Jacobs says the method will likely be adopted in an annual screening program. This article was originally published on UNSW Newsroom, to read the full article click here.
A Soldier Saved Posted on April 27, 2015March 14, 2018 by Carly du Toit “I support the ACRF because my son is alive and well today thanks to the great strides being made in cancer research around diagnosis and treatment. My 23 year old son was diagnosed with testicular cancer during his final year of training to become an Officer in the Australian Army. Within days of hearing the news he had to go in for surgery and had an orchiectomy. Unfortunately though, at that point, the cancer had already spread to his lymph nodes and he was told that he would have to undergo chemotherapy treatments. He began his chemo immediately following his graduation from the Royal Military College in December 2013. But as bad luck would have it, he didn’t get an all clear, even after four rounds of chemo. So the next step was an extensive open abdominal surgical procedure, known as a retroperitoneal lymph node dissection (RPLND) which was followed by a lengthy recovery. Fortunately, he’s now in remission and has embarked on what will be a proud military career. Becoming a Partner in the Cure was a small way for me to help others become cancer survivors like my son.” Simon Toovey, Regular Giver of the Month. Share your story
Existing blood disorder medicine shows promise in treating certain stomach and bowel cancers Posted on February 18, 2014February 25, 2018 by Carly du Toit Cancer scientists at the Walter and Eliza Hall Institute (WEHI) have recently discovered an existing treatment for a blood disorder could potentially also treat stomach and bowel cancer – two of the most common cancers worldwide. Pre-clinical trials have found an existing class of medicines called ‘JAK inhibitors’ reduce the growth of inflammation often associated with stomach and bowel cancer. JAK inhibitors are currently being used to treat myelofibrosis and are currently in clinical trials for the treatment of other conditions such as leukaemia, lymphoma, lupus and rheumatoid arthritis. Continue reading “Existing blood disorder medicine shows promise in treating certain stomach and bowel cancers”
Research is winning the fight against cancer! Posted on September 24, 2012February 25, 2018 by Carly du Toit Cancer survival rates have increased by 19% in just a couple of decades, highlighting the fantastic success of great cancer research in Australia. According to the latest report by the Australian Institute of Health and Welfare (AIHW) the average 5-year survival rate for all types of cancer increased from 47% in 1982 to 66% in 2010. “Research is the key to beating cancer, and these statistics are evidence of how progress in the labs is being translated into positive health outcomes for Australians.” Said ACRF Chief Executive, David Brettell. “The funding we award to cancer research teams across the country is used specifically to speed up discoveries – effectively working to save lives by saving time. “Given continued investment in cancer research in Australia, we would very much expect and look forward to these survival rates improving even further in the very near future.” Continue reading “Research is winning the fight against cancer!”
ACRF-funded cancer research centre will speed up the fight against Leukaemia Posted on April 3, 2012February 25, 2018 by Carly du Toit A new research centre set to fast-track leukaemia discoveries and other types of blood cancer research from the lab to the hospital bedside was opened today by the Victorian Minister for Health, David Davis. Established through a $1 million grant from the ACRF, The Australian Cancer Research Foundation (ACRF) Centre for Translational Research will provide new hope to thousands of people with blood cancers. The facility is located at The Royal Melbourne Hospital, which sees more than 120 new leukaemia cases and performs some 80 bone marrow transplants each year. The Translational Research Centre will therefore provide a seamless link between the Hospital and collaborating research facilities, including the Walter and Eliza Hall Institute of Medical Research, the University of Melbourne and The Royal Melbourne’s Diagnostic Haematology Laboratory and clinical services. Executive Director of Research at The Royal Melbourne Hospital, Prof Ingrid Winship said such a centre was vital to improve outcomes for patients. Continue reading “ACRF-funded cancer research centre will speed up the fight against Leukaemia”
